NDA 8814, held by Medpointe Pharm Hlc. Cryptenamine Acetates.
As of Nov 14, 2026, NDA 8814 (Unitensen), held by Medpointe Pharm Hlc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Unitensen260CSR UNIT/ML ยท injectable;injection | Cryptenamine Acetates | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
